Cargando…

Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens

BACKGROUND: Allergen immunotherapy is a recognised intervention in patients with allergies not responding to standard pharmacotherapy or in whom pharmacotherapy is contraindicated. We describe the sublingual immunotherapy (SLIT) regimens used in children and adolescents with house dust mite (HDM) re...

Descripción completa

Detalles Bibliográficos
Autores principales: Trebuchon, Florence, Lhéritier-Barrand, Michèle, David, Marie, Demoly, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047545/
https://www.ncbi.nlm.nih.gov/pubmed/24910771
http://dx.doi.org/10.1186/2045-7022-4-15
_version_ 1782480411377532928
author Trebuchon, Florence
Lhéritier-Barrand, Michèle
David, Marie
Demoly, Pascal
author_facet Trebuchon, Florence
Lhéritier-Barrand, Michèle
David, Marie
Demoly, Pascal
author_sort Trebuchon, Florence
collection PubMed
description BACKGROUND: Allergen immunotherapy is a recognised intervention in patients with allergies not responding to standard pharmacotherapy or in whom pharmacotherapy is contraindicated. We describe the sublingual immunotherapy (SLIT) regimens used in children and adolescents with house dust mite (HDM) respiratory allergies in France and assess the efficacy and safety of this treatment. METHODS: This was a sub-analysis of paediatric patients included in a previous retrospective, observational, multicentre study. Inclusion criteria were: age 5–17 years; respiratory allergy and proven sensitisation to HDM; at least 2 years follow-up after SLIT initiation. The following data were recorded at SLIT initiation: clinical characteristics; sensitisation profile; concomitant symptomatic medications; details of SLIT protocol. During follow-up and at the end of treatment the following data were recorded: any changes to SLIT treatment; any changes to symptomatic medications; symptom progression; adverse events. SLIT efficacy, patient compliance and satisfaction, and safety were assessed. RESULTS: 736 paediatric patients were included in this analysis. Most patients (95.5%) had allergic rhinitis, which was moderate to severe persistent in 62.8%. Allergic asthma was present in 64.0% and was mild to moderate persistent in 52.7% of these patients. The majority of patients had rhinitis with asthma (59.5%). Three-hundred and seventy five (62.3%) patients were polysensitised. Compliance was good in 86.5% of patients and SLIT was effective in 83.8%. Symptoms of rhinitis and asthma were improved in 64.6% and 64.3% of patients, respectively. A decrease in symptomatic medication was observed following SLIT initiation in patients with rhinitis and/or asthma. SLIT was well tolerated with mainly local reactions reported. CONCLUSIONS: HDM SLIT appears to be effective in children and adolescents with rhinitis and/or asthma due to HDM allergens, with no tolerability issues and similar benefits as in adults.
format Online
Article
Text
id pubmed-4047545
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40475452014-06-07 Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens Trebuchon, Florence Lhéritier-Barrand, Michèle David, Marie Demoly, Pascal Clin Transl Allergy Research BACKGROUND: Allergen immunotherapy is a recognised intervention in patients with allergies not responding to standard pharmacotherapy or in whom pharmacotherapy is contraindicated. We describe the sublingual immunotherapy (SLIT) regimens used in children and adolescents with house dust mite (HDM) respiratory allergies in France and assess the efficacy and safety of this treatment. METHODS: This was a sub-analysis of paediatric patients included in a previous retrospective, observational, multicentre study. Inclusion criteria were: age 5–17 years; respiratory allergy and proven sensitisation to HDM; at least 2 years follow-up after SLIT initiation. The following data were recorded at SLIT initiation: clinical characteristics; sensitisation profile; concomitant symptomatic medications; details of SLIT protocol. During follow-up and at the end of treatment the following data were recorded: any changes to SLIT treatment; any changes to symptomatic medications; symptom progression; adverse events. SLIT efficacy, patient compliance and satisfaction, and safety were assessed. RESULTS: 736 paediatric patients were included in this analysis. Most patients (95.5%) had allergic rhinitis, which was moderate to severe persistent in 62.8%. Allergic asthma was present in 64.0% and was mild to moderate persistent in 52.7% of these patients. The majority of patients had rhinitis with asthma (59.5%). Three-hundred and seventy five (62.3%) patients were polysensitised. Compliance was good in 86.5% of patients and SLIT was effective in 83.8%. Symptoms of rhinitis and asthma were improved in 64.6% and 64.3% of patients, respectively. A decrease in symptomatic medication was observed following SLIT initiation in patients with rhinitis and/or asthma. SLIT was well tolerated with mainly local reactions reported. CONCLUSIONS: HDM SLIT appears to be effective in children and adolescents with rhinitis and/or asthma due to HDM allergens, with no tolerability issues and similar benefits as in adults. BioMed Central 2014-04-29 /pmc/articles/PMC4047545/ /pubmed/24910771 http://dx.doi.org/10.1186/2045-7022-4-15 Text en Copyright © 2014 Trebuchon et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Trebuchon, Florence
Lhéritier-Barrand, Michèle
David, Marie
Demoly, Pascal
Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens
title Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens
title_full Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens
title_fullStr Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens
title_full_unstemmed Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens
title_short Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens
title_sort characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047545/
https://www.ncbi.nlm.nih.gov/pubmed/24910771
http://dx.doi.org/10.1186/2045-7022-4-15
work_keys_str_mv AT trebuchonflorence characteristicsandmanagementofsublingualallergenimmunotherapyinchildrenwithallergicrhinitisandasthmainducedbyhousedustmiteallergens
AT lheritierbarrandmichele characteristicsandmanagementofsublingualallergenimmunotherapyinchildrenwithallergicrhinitisandasthmainducedbyhousedustmiteallergens
AT davidmarie characteristicsandmanagementofsublingualallergenimmunotherapyinchildrenwithallergicrhinitisandasthmainducedbyhousedustmiteallergens
AT demolypascal characteristicsandmanagementofsublingualallergenimmunotherapyinchildrenwithallergicrhinitisandasthmainducedbyhousedustmiteallergens